Drug safety

FDA approves cell-based blood cancer therapy. The Wall Street Journal reports the FDA on Monday cleared a cell-based therapy for blood cancer from Johnson & Johnson for adults among whom other drugs have proven ineffective. The technology was first developed in China, and its US approval suggests a new path forward for drugmakers seeking to bring Chinese therapies to the US.